Cargando…

Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT(1-2)N(+) Breast Cancer Patients: A Single Center Experience and Review of Current Literature

PURPOSE: Postmastectomy radiotherapy (PMRT) after neoadjuvant chemotherapy (NAC) in breast cancer patients with initial clinical stage cT(1-2)N(+), especially for those who achieved ypT(1-2)N(0), is still controversial. This study was to evaluate the survival prognosis of cT(1-2)N(+) patients after...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Meng, Chen, Huihui, Deng, Hao, Jin, Yao, Wang, Gui, Zhang, Kun, Ma, Hong, Chen, Yiding, Zhang, Suzhan, Zhou, Jiaojiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152099/
https://www.ncbi.nlm.nih.gov/pubmed/35656513
http://dx.doi.org/10.3389/fonc.2022.881047
_version_ 1784717569414922240
author Luo, Meng
Chen, Huihui
Deng, Hao
Jin, Yao
Wang, Gui
Zhang, Kun
Ma, Hong
Chen, Yiding
Zhang, Suzhan
Zhou, Jiaojiao
author_facet Luo, Meng
Chen, Huihui
Deng, Hao
Jin, Yao
Wang, Gui
Zhang, Kun
Ma, Hong
Chen, Yiding
Zhang, Suzhan
Zhou, Jiaojiao
author_sort Luo, Meng
collection PubMed
description PURPOSE: Postmastectomy radiotherapy (PMRT) after neoadjuvant chemotherapy (NAC) in breast cancer patients with initial clinical stage cT(1-2)N(+), especially for those who achieved ypT(1-2)N(0), is still controversial. This study was to evaluate the survival prognosis of cT(1-2)N(+) patients after NAC with or without PMRT, and to discuss the selection of patients who may omit PMRT. PATIENTS AND METHODS: From January 2005 to December 2017, 3055 female breast cancer patients underwent mastectomy in our medical center, among whom 215 patients of cT(1-2)N(+) stage, receiving NAC with or without PMRT were finally analyzed. The median follow-up duration was 72.6 months. The primary endpoint was disease-free survival (DFS), and secondary endpoint was overall survival (OS). Comparison was conducted between PMRT and non-PMRT subgroups. RESULTS: Of the 215 eligible patients, 35.8% (77/215) cT(1-2)N(+) patients achieved ypT(0-2)N(0) after NAC while 64.2% (138/215) of the patients remained nodal positive (ypT(0-2)N(+)). The 5-year DFS of ypT(0-2)N(0) non-PMRT was 79.5% (95% confidence interval [CI] 63.4-95.6%). No statistically significant difference was observed between the ypT(0-2)N(0) PMRT and non-PMRT subgroups for the 5-year DFS (78.5% vs 79.5%, p = 0.673) and OS (88.8% vs 90.8%, p = 0.721). The 5-years DFS didn’t obviously differ between the ypT(0-2)N(0) non-PMRT subgroup and cT(1-2)N(0) subgroup (79.5% vs 93.3%, p = 0.070). By using Cox regression model in multivariate analyses of prognosis in ypT(0-2)N(+) PMRT subgroup, HER2 overexpression and triple-negative breast cancer were significantly poor predictors of DFS and OS, while ypN stage was significant independent predictors of OS. CONCLUSION: An effective response to NAC (ypT(0-2)N(0)) indicates a sufficiently favorable prognosis, and PMRT might be omitted for cT(1-2)N(+) breast cancer patients with ypT(0-2)N(0) after NAC.
format Online
Article
Text
id pubmed-9152099
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91520992022-06-01 Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT(1-2)N(+) Breast Cancer Patients: A Single Center Experience and Review of Current Literature Luo, Meng Chen, Huihui Deng, Hao Jin, Yao Wang, Gui Zhang, Kun Ma, Hong Chen, Yiding Zhang, Suzhan Zhou, Jiaojiao Front Oncol Oncology PURPOSE: Postmastectomy radiotherapy (PMRT) after neoadjuvant chemotherapy (NAC) in breast cancer patients with initial clinical stage cT(1-2)N(+), especially for those who achieved ypT(1-2)N(0), is still controversial. This study was to evaluate the survival prognosis of cT(1-2)N(+) patients after NAC with or without PMRT, and to discuss the selection of patients who may omit PMRT. PATIENTS AND METHODS: From January 2005 to December 2017, 3055 female breast cancer patients underwent mastectomy in our medical center, among whom 215 patients of cT(1-2)N(+) stage, receiving NAC with or without PMRT were finally analyzed. The median follow-up duration was 72.6 months. The primary endpoint was disease-free survival (DFS), and secondary endpoint was overall survival (OS). Comparison was conducted between PMRT and non-PMRT subgroups. RESULTS: Of the 215 eligible patients, 35.8% (77/215) cT(1-2)N(+) patients achieved ypT(0-2)N(0) after NAC while 64.2% (138/215) of the patients remained nodal positive (ypT(0-2)N(+)). The 5-year DFS of ypT(0-2)N(0) non-PMRT was 79.5% (95% confidence interval [CI] 63.4-95.6%). No statistically significant difference was observed between the ypT(0-2)N(0) PMRT and non-PMRT subgroups for the 5-year DFS (78.5% vs 79.5%, p = 0.673) and OS (88.8% vs 90.8%, p = 0.721). The 5-years DFS didn’t obviously differ between the ypT(0-2)N(0) non-PMRT subgroup and cT(1-2)N(0) subgroup (79.5% vs 93.3%, p = 0.070). By using Cox regression model in multivariate analyses of prognosis in ypT(0-2)N(+) PMRT subgroup, HER2 overexpression and triple-negative breast cancer were significantly poor predictors of DFS and OS, while ypN stage was significant independent predictors of OS. CONCLUSION: An effective response to NAC (ypT(0-2)N(0)) indicates a sufficiently favorable prognosis, and PMRT might be omitted for cT(1-2)N(+) breast cancer patients with ypT(0-2)N(0) after NAC. Frontiers Media S.A. 2022-05-17 /pmc/articles/PMC9152099/ /pubmed/35656513 http://dx.doi.org/10.3389/fonc.2022.881047 Text en Copyright © 2022 Luo, Chen, Deng, Jin, Wang, Zhang, Ma, Chen, Zhang and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Luo, Meng
Chen, Huihui
Deng, Hao
Jin, Yao
Wang, Gui
Zhang, Kun
Ma, Hong
Chen, Yiding
Zhang, Suzhan
Zhou, Jiaojiao
Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT(1-2)N(+) Breast Cancer Patients: A Single Center Experience and Review of Current Literature
title Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT(1-2)N(+) Breast Cancer Patients: A Single Center Experience and Review of Current Literature
title_full Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT(1-2)N(+) Breast Cancer Patients: A Single Center Experience and Review of Current Literature
title_fullStr Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT(1-2)N(+) Breast Cancer Patients: A Single Center Experience and Review of Current Literature
title_full_unstemmed Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT(1-2)N(+) Breast Cancer Patients: A Single Center Experience and Review of Current Literature
title_short Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT(1-2)N(+) Breast Cancer Patients: A Single Center Experience and Review of Current Literature
title_sort postmastectomy radiotherapy after neoadjuvant chemotherapy in ct(1-2)n(+) breast cancer patients: a single center experience and review of current literature
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152099/
https://www.ncbi.nlm.nih.gov/pubmed/35656513
http://dx.doi.org/10.3389/fonc.2022.881047
work_keys_str_mv AT luomeng postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature
AT chenhuihui postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature
AT denghao postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature
AT jinyao postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature
AT wanggui postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature
AT zhangkun postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature
AT mahong postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature
AT chenyiding postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature
AT zhangsuzhan postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature
AT zhoujiaojiao postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature